There may be slightly higher risks associated with pre-market and after-hours trading than during regular market hours. Due to the fact that issuers often announce critical financial information outside of regular trading hours, extended-hours trading may result in wider spreads for particular securities. After-hours trades for Cue Biopharma Inc (CUE) shows that investor sentiment remained same, with the stock’s consolidated last price to $2.55. The Cue Biopharma Inc has recorded 7,604 volume in the after hours trading session. The stock was recently discussed on Yahoo Finance as it revealed that Cue Biopharma Presents New Positive Data from Phase 1 Trials of CUE-101 in Head and Neck Cancer and CUE-102 in Wilms’ Tumor 1 Positive Cancers at SITC 2023.
As a NASDAQ listed company, CUE falls under the Healthcare sector while operating within the Biotechnology industry segment. At the end of the last regular session, the stock closed at $2.55 and fluctuated between $2.8400 as its day high and $2.4800 as its day low. The current market capitalization of Cue Biopharma Inc is $114.65M. A total of 0.5 million shares were traded on the day, compared to an average of 309.89K shares.
Aside from predicting where a stock will go, investors also consider insider trades as an indicator of the stock’s future direction. During the recent three months, CUE has seen 2 BUY and 0 SELL insider trades, representing the acquisition of 7,000 and the disposition of 0 shares. Over the last 12 months, there were 3 BUYs and 1 SELLs from insiders. Insiders purchased 16,682 shares during that period but sold 9,325.
In the most recent transaction, Suri Anish bought 4,000 shares of CUE for 2.76 per share on Aug 25. After the transaction, the PRESIDENT AND CSO now owns 135,638 company shares. In a previous transaction on Aug 14, PASSERI DANIEL R bought 3,000 shares at 2.86 per share. CUE shares that CHIEF EXECUTIVE OFFICER owns now total 134,578.
Among the insiders who sold shares, Kiener Peter A disposed of 9,325 shares on Mar 23 at a per-share price of $3.28. This resulted in the Director holding 357 shares of CUE after the transaction.
In spite of price targets being rarely accurate, it tends to exert some kind influence from time to time, and was often accepted by the market as having some value. According to analysts who have offered 12-month price targets for CUE in the last 3 months, the mean price target is $10.25 with high estimates of $15.00 and low estimates of $8.00. In terms of 52-week highs and lows, CUE has a high of $5.12 and a low of $1.70.
As of this writing, CUE has an earnings estimate of -$0.34 per share for the current quarter. EPS was calculated based on a consensus of 4 estimates, with a high estimate of -$0.27 per share and a lower estimate of -$0.46.
Balance Sheet Annually/Quarterly
The balance sheet of a company shows what assets and liabilities a company has, as well as the amount, equity investors have invested. With the help of this information, a company’s financial ratios can be calculated to give investors an overview of the company’s prospects. CUE’s latest balance sheet shows that the firm has $64.37M in Cash & Short Term Investments as of fiscal 2021. There were $10.05M in debt and $12.79M in liabilities at the time. Its Book Value Per Share was $0.95, while its Total Shareholder’s Equity was $65.49M.
The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for CUE is Buy with a score of 5.00.